Apple Inc (NASDAQ:AAPL) is preparing to sell its first wearable device this October, aiming to produce 3 million to 5 million smartwatches a month in its initial run, the Nikkei reported on Friday, citing an unidentified parts supplier and sources familiar with the matter. Apple Inc. (NASDAQ:AAPL) net profit margin is 21.40% and weekly performance is 1.98%. On last trading day company shares ended up $92.22. Analys,ts mean target price for the company is $642.17. Apple Inc. (NASDAQ:AAPL) distance from 50-day simple moving average (SMA50) is -83.90%.
On June 6, Shares of Halcon Resources Corp (NYSE:HK) hit a new 52-week high during mid-day trading on Friday after Wunderlich raised their price target on the stock from $7.00 to $9.00, American Banking Newsreports. Wunderlich currently has a buy rating on the stock. Halcon Resources Corp traded as high as $6.47 and last traded at $6.38, with a volume of 2,869,076 shares changing hands. The stock had previously closed at $6.34. Halcon Resources Corp (NYSE:HK) shares advanced 0.95% in last trading session and ended the day on $6.40. Gross Margin is 76.60% and its return on assets is -23.00 %. Halcon Resources Corp (NYSE:HK) quarterly performance is 56.86%.
On June 3, 2014, Melco Crown Entertainment Limited (ADR) (NASDAQ:MPEL) a developer, owner and operator of casino gaming and entertainment resort facilities in Asia, announced that the development of the Company’s Studio City project is on track for a mid-2015 opening. Melco Crown Entertainment Ltd (ADR) (NASDAQ:MPEL) shares moved down -2.75% in last trading session and was closed at $32.55, while trading in range of $32.44- $33.25. Melco Crown Entertainment Ltd (ADR) (NASDAQ:MPEL) year to date (YTD) performance is -15.96%.
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) received approval of the New Drug Application (NDA) for BUNAVAIL (buprenorphine and naloxone) buccal film (CIII) from the U.S. Food and Drug Administration (FDA). BUNAVAIL is indicated for the maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. BDSI expects to launch BUNAVAIL late in the third quarter of 2014. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) ended the last trading day at $10.00. Company weekly volatility is calculated as 4.68 % and price to cash ratio as 5.49. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) showed a positive weekly performance of 4.49%.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) today announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, received notice that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Jublia® (efinaconazole 10% topical solution), the first topical triazole approved for the treatment of onychomycosis of the toenails. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) net profit margin is -13.10% and weekly performance is -2.86%. On last trading day company shares ended up $127.46. Analysts mean target price for the company is $52.38. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) distance from 50-day simple moving average (SMA50) is -1.41%.